Huge news in APOL1 nephropathy - ten tweets to fill you in here:
This week, we aim for an INFINITe allograft lifespan. or flozination in kidney transplant.
This week, we will discuss the POTCAST trial. It is a cardiology trial - but potassium belongs to nephrology.
This week, we will discuss the VALIANT study, pegcetacoplan in C3G and IC MPGN.
2025 was rich in successful stories. Here are the top 10 that impressed our audience.
Huge news in APOL1 nephropathy - ten tweets to fill you in here:
Welcome to #TenTweetNephJC
— Nephrology Journal Club (@NephJC) May 12, 2023
✳️10 tweets #NephJC catch-up ✳️
On 4/25-26, we discussed the phase II study examining inaxaplin treatment, a small molecule inhibitor, in APOL1 nephropathy. This is the first drug specifically targeting this disease.
Join us here for the recap! pic.twitter.com/LApAHkYn10